Maricann Announces Termination of Equity Financing by Underwriters and Provides Operations Update

TORONTO, March 01, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (OTCQB:MRRCF) (FRANKFURT:75M) “Maricann” or the “Company”) announced today that it has received a notice of termination from Eight Capital, Canaccord Genuity Corp., GMP Securities L.P., Industrial Alliance Securities Inc. and Clarus Securities Inc. (the “Underwriters”), terminating their obligations pursuant to an underwriting agreement dated February 2, 2018 (the “Underwriting Agreement”), whereby the Underwriters agreed to purchase on a bought deal basis 17,500,000 units of the Company, for gross proceeds of $70,000,000 (the “Financing”) at a price of $4.00 per unit. The notice of termination received from the Underwriters did not provide the reason for the Underwriters terminating their obligations under the Underwriting Agreement.

Interim Chairman Paul Pathak commented, We are disappointed to have received the notice of termination and are considering our options for further action. In the meantime, the Company has a focus on moving forward from a solid position to build increased shareholder value. We appreciate the constructive dialogue we are having with many of our shareholders.

The Company remains committed to continue efforts to complete the prospectus qualification process for the distribution of the units underlying the 20,125,000 special warrants issued on January 9, 2018. As previously announced each special warrant will entitle the holder to receive, upon the exercise thereof, for no additional consideration, 1.05 units (instead of one (1) unit) provided, however, that any fractional entitlement to such units will be rounded down to the nearest whole unit.

Maricann continues to focus on its strategy to deliver growth and value as a future leader of the Canadian cannabis sector.  The Company’s operations are fully-funded, with approximately $48.2MM in the bank. The construction of Maricann’s state-of-the-art 942,000 sq. ft. flagship facility in Langton, Ontario continues on schedule, with first planting planned to occur on March 23, 2018, subject to Health Canada approval. Photos of construction progress are available on the Company’s website at

“At this time it’s business as usual, we persevere with focus on executing our business plan, all material agreements pertaining to operations remain intact and the Company is moving full speed ahead in all operational areas. We are fully financed for existing commitments with approximately $48.2MM of cash on hand, following the closing of the special warrants financing where the Company raised $40.25 MM in gross proceeds,” said Benjamin Ward, CEO of Maricann Group Inc.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth.

For more information about Maricann, please visit our website at

Original Press Release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter